NCT02515227View on ClinicalTrials.gov

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 6, 2016

Primary Completion Date

March 14, 2020

Study Completion Date

March 14, 2020

Conditions
Melanoma
Interventions
BIOLOGICAL

6MHP

6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

DRUG

Pembrolizumab

Humanized monoclonal antibody (mAb) specific for PD-1.

Trial Locations (1)

22908

University of Virginia Cancer Center, Charlottesville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Craig L Slingluff, Jr

OTHER

NCT02515227 - Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab | Biotech Hunter | Biotech Hunter